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Abstract
Normal glucose homeostasis is characterized by appropriate insulin secretion and low HbA1c. Gene expression signatures
associatedwith these two phenotypes could be essential for islet function and pathophysiologyof type 2 diabetes (T2D). Herein,
we employed a novel approach to identify candidate genes involved in T2D by correlating isletmicroarray gene expression data
(78 donors) with insulin secretion and HbA1c level. The expression of 649 genes (P < 0.05) was correlated with insulin secretion
and HbA1c. Of them, ﬁve genes (GLR1A, PPP1R1A, PLCDXD3, FAM105A and ENO2) correlated positively with insulin secretion/
negatively with HbA1c and one gene (GNG5) correlated negatively with insulin secretion/positively with HbA1c were followed
up. The ﬁve positively correlated genes have lower expression levels in diabetic islets, whereas GNG5 expression is higher.
Exposure of human islets to high glucose for 24 h resulted in up-regulation of GNG5 and PPP1R1A expression, whereas the
expression of ENO2 and GLRA1 was down-regulated. No effect was seen on the expression of FAM105A and PLCXD3. siRNA
silencing in INS-1 832/13 cells showed reduction in insulin secretion for PPP1R1A, PLXCD3, ENO2, FAM105A and GNG5 but not
GLRA1. Although no SNP in these gene loci passed the genome-wide signiﬁcance for association with T2D in DIAGRAM+
database, four SNPs inﬂuenced gene expression in cis in human islets. In conclusion, we identiﬁed and conﬁrmed PPP1R1A,
FAM105A, ENO2, PLCDX3 and GNG5 as potential regulators of islet function. We provide a list of candidate genes as a resource
for exploring their role in the pathogenesis of T2D.
Introduction
Diabetes is a globally expanding health issue, causing a great bur-
den on healthcare in both developing and industrialized coun-
tries (1). The incidence of type 2 diabetes (T2D) is increasing
globally and expected to affect >550 million people by 2030
(www.idf.org/diabetesatlas), of which T2D accounts for >90% of
cases. T2D is characterized by increased blood glucose owing to
defects in insulin secretion from the pancreatic beta cells and
impaired insulin action.
The pathogenesis of T2D is still not fully understood. It is well
established that T2D develops from an interaction between gen-
etic susceptibility and awesternized lifestyle characterized by in-
creasing obesity. In the past 10 years, several genome-wide
association studies (GWAS) have discovered >100 genetic var-
iants associated with T2D or blood glucose/insulin secretion
(2–12). Despite this large number, these variants can only explain
10–15% of the heritability of the disease (13,14). One main reason
is that the effect size of each individual variant is very modest.
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The key question is therefore whether more variants (close to
1000) would be able to explain the full genetic background of
T2D or whether we need more holistic approaches combining
DNA, RNA and protein information (15).
Diabetes is deﬁned as a condition of chronic hyperglycemia,
which can be monitored by measuring glycated hemoglobin A1c
(HbA1c) (www.who.int/diabetes/publications/report-hba1c_2011).
In untreated individuals, one would expect elevated HbA1c to be
associated with impaired insulin secretion and vice versa, i.e. a
low HbA1c value in normoglycemic individuals with normal or
high insulin secretion.
Herein, we introduced a novel approach by correlating islet
gene expression with insulin secretion and HbA1c levels in islets
from 78 organ donors. Five genes correlated positively with insu-
lin secretion/negatively with HbA1c (GLR1A, PPP1R1A, PLCDXD3,
FAM105A and ENO2), whereas one gene (GNG5) correlated nega-
tively with insulin secretion and positively with HbA1c. We then
followed up these ﬁndings by siRNA silencing of the genes in an
INS-1 cell line. We also analyzed whether SNPs in these genetic
loci are associated with T2D in the DIAGRAM+ database or
could inﬂuence gene expression in cis expression quantitative
trait loci (eQTLs).
Results
Correlation between gene expression and insulin
secretion and Hba1c
In this study, we utilized human pancreatic islet microarray
expression data (GeneChip® Human Gene 1.0 ST) obtained from
78 donors (68 non-diabetic and 10 diabetic, see Materials and
Methods). Each donor was characterized by measuring insulin
response to glucose in the islet preparation and glycemic control
(HbA1c) from the same individual. Spearman’s test was used to
perform a global correlation of gene expression (adjusted for
age and sex) with insulin secretion and HbA1c in the same 78
donors (each array has ∼22 000 genes) (Fig. 1). The expression of
649 genes (P-value < 0.05) showed signiﬁcant correlation with
insulin secretion and HbA1c levels (Fig. 1B). Of these, 518 genes
were positively correlated with insulin secretion and negatively
with HbA1c, 128 genes were negatively correlated with insulin
secretion and positively with HbA1c, 2 genes were positively
correlated both with HbA1c and insulin secretion and only
1 gene negatively correlated with HbA1c and insulin secretion
(Fig. 1B, Supplementary Material, Table S1).
Figure 1. Spearman correlation of the expression of 22 000 genes on the chip against insulin secretion andHbA1c levels in human islets (A). (B) In total, 649 genes showed a
signiﬁcant correlation with insulin and HbA1c (P-value < 0.05). Of these, 518 genes correlated positively with insulin secretion and negatively with HbA1c (green square),
128 genes correlated negatively with insulin secretion and positively with Hba1c (red square), 2 genes correlated positively both with insulin secretion and HbA1c (black
square), and one gene correlated negatively with insulin secretion and HbA1c (blue square). The X-axis and Y-axis scales represent the correlation coefﬁcient. FDR and
Bonferroni thresholds for each correlation are shown in SupplementaryMaterial, Table S1. (C) Correlation ofmean centroid of the 11 positively correlated genes to insulin
secretion and HbA1c level. (D) Correlation of mean centroid of the 10 negatively correlated genes to insulin secretion and HbA1c levels.
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Ranking of positively and negatively correlated genes
We ranked the 518 genes showing positive correlation with insu-
lin and negative correlation with HbA1c (+insulin/−HbA1c) and
the 128 genes showing negative correlation with insulin and
positive with HbA1c (insulin/+HbA1c) based upon the sum of
their P-value correlation with insulin and HbA1c levels, given a
rank from 1 to 518 or 128, respectively; the lowest ranking sum re-
presents the top-ranked genes. We selected the 10 top-ranked
genes from each group for further functional analyses.
The top 10 ranked genes from the positively correlated group
were GLRA1, ATP2A3, MCF2L2, PTEN, PPP1R1A, SYT13, WSCD2,
TAGLN3, PLCXD3 and ENO2 (Table 1A). To ensure that the 10
selected genes are indeed expressed in β-cells, the genes were
ﬁltered based upon recently published RNA-sequencing expres-
sion data from sorted human pancreatic endocrine cells (16).
All of them showed higher expression in β-cells compared with
α-cells or exocrine cells. Analysis of the expression proﬁle of
these genes in the islet expression array revealed a signiﬁcant
down-regulation in diabetic/hyperglycemic donors compared
with non-diabetic/normoglycemic (Fig. 2). Plotting expression
centroid of the top 10 positively correlated genes against insulin
secretion and HbA1c level showed a strong positive correlation
with insulin secretion and an inverse correlation with HbA1c
(Fig. 1C). Moreover, analysis of the co-expression of these genes
with glucagon (GCG) expression (probes for the insulin gene
were not on the affy chip) showed a signiﬁcant positive
Table 1. Ten top-ranked genes ordered by the lowest sum of P-value for the correlation with HbA1c and insulin secretion
Gene Name p-insulin p-HbA1c
A: genes correlated positively with insulin secretion and negatively with HbA1c
GLRA1 Glycine receptor, alpha 1 0.0006 0.00001
ATP2A3 ATPase, Ca++ transporting, ubiquitous 0.0001 0.00004
MCF2L2 MCF.2 cell line-derived transforming sequence-like2 0.0020 0.00000
PTEN Phosphatase and tensin homolog 0.0025 0.00000
PPP1R1A Protein phosphatase 1, regulatory (inhibitor) subunit 1A 0.0022 0.00002
SYT13 Synaptotagmin XIII 0.0012 0.00011
WSCD2 WSC domain containing 2 0.0010 0.00016
TAGLN3 Transgelin 3 0.0017 0.00009
PLCXD3 Phosphatidylinositol-speciﬁc phospholipase C, X domain 0.0025 0.00004
ENO2 Endolase 2 (gamma, neuronal) 0.0011 0.00022
FAM105A Family with sequence similarity 105, member A 0.0043 0.000004
B: genes correlated negatively with insulin secretion and positively with HbA1c.
B3GALNT2 Beta-1,3-N-Acetylgalactosaminyltransferase 2 0.00268 0.00206
KCNH8 Potassium Voltage-Gated Channel, Subfamily H, Member 8 0.00010 0.00543
MYC V-Myc Avian Myelocytomatosis Viral Oncogene Homolog 0.00671 0.00379
IL1R2 Interleukin 1 Receptor, Type II. 0.01557 0.00020
RPGR Retinitis Pigmentosa GTPase Regulator 0.00442 0.00861
KLF6 Kruppel-Like Factor 6 0.01621 0.00173
CCL13 Chemokine (C-C Motif ) Ligand 13 0.00323 0.01161
SLC16A7 Solute Carrier Family 16, Member 7 0.00738 0.00887
ATP4A ATPase, H+/K+ Exchanging, Alpha Polypeptide 0.01333 0.00388
GNG5 Guanine Nucleotide Binding Protein (G Protein), Gamma 5 0.02021 0.00084
Figure 2. Fold change differences in islet expression of the top correlated genes between diabetic/hyperglycemic and nondiabetic/normoglycemic donors. The expression
of the positive correlated genes GLRA1 (P = 0.001), ATP2A3 (P = 0.002), MCF2L2 (P = 0.003), PTEN (P = 0.007), PPP1R1A (P = 0.0002), SYT13 (P = 0.001),WSCD2 (P = 0.003), TAGLN3
(P = 0.003), PLCXD3 (P = 0.0001), ENO2 (P = 0.003) and FAM105A (P = 0.0003) was lower in diabetic/hyperglycemic (n = 23) donors comparedwith nondiabetic/normoglycemic
(n = 43). The expression of the negative correlated genes B3GALNT2 (P = 0.047), MYC (P = 0.001), IL1R2 (P = 0.00002), SLC16A7 (P = 0.01) and GNG5 (P = 0.007) was lower in
diabetic/hyperglycemic donors compared with nondiabetic/normoglycemic, whereas no change was seen in the expression of KCNH8, RPGR, KLF6, CCL13 and ATP4A.
Bars represent mean ± SEM.
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correlation with GCG (Fig. 3). Some genes, e.g. ATP2A3 (17–19),
PTEN (20,21) and SYT13 (22), have previously been implicated in
insulin secretion and were not further examined. FAM105A was
ranked as number 12, but because it belongs to the genes with
unknown function in islets, we included it for functional fol-
low-up. Hence, of the positively correlated genes, we selected
ﬁve genes GLRA1, PPP1R1A, PLCXD3, ENO2 and FAM105A for fur-
ther investigations.
Of the top-ranked negatively correlated genes B3GALNT2,
KCNH8, MYC, IL1R1, RPGR, KLF6, CCL13, SLC16A7, ATP4A and
GNG5 (Table 1B), the expression of B3GALNT2, MYC, IL1R1,
SLC16A7 and GNG5 was higher in diabetic/hyperglycemic com-
pared with non-diabetic/normoglycemic donors (Fig. 2). The
expression centroid of the top 10 negative genes showed a strong
negative correlation with insulin secretion and positive correl-
ation with HbA1c (Fig. 1D). Moreover, these 10 genes were signiﬁ-
cantly negatively correlated with glucagon (GCG) expression
(Supplementary Material, Fig. S1). KCNH8 expression showed
no correlation with GCG. Out of the 10 negatively correlated
genes, 8 showed higher expression in pancreatic α-cells com-
pared with β-cells, CCL13 was equally expressed and GNG5
showed higher expression in pancreatic β-cells than that in
α-cells (16). Therefore, only GNG5 was selected for functional
studies.
Effect of glucose exposure on gene expression
The correlation with high HbA1c can either be the cause or con-
sequence of elevated glucose levels. To address this question, we
exposed human pancreatic islets from 51 donors to low (5.5 m)
and high (18.9 m) glucose concentration for 24 h, assuming that
genes whose expression increased after exposure to 24 h of glu-
cose would represent secondary changes but still could mediate
glucotoxic effects on islets. Given that these experiments were
performed a year later than the microarray experiments, we
switched to RNA sequencing for the glucose exposure experi-
ments. Short-term exposure to high glucose showed a signiﬁcant
up-regulation of the expression of GNG5 (P = 0.0001) and PPP1R1A
(P = 0.0002), whereas the expression of ENO2 (P = 0.002) and
GLRA1 (P = 0.02) was down-regulated (Fig. 4). No effect of acute
high glucose exposure was seen on the expression of FAM105A
(P = 0.9) and PLCXD3 (P = 0.4) (Fig. 4).
Down-regulation of gene expression in clonal
rat β-cells (INS-1)
To explore whether the down-regulation of genes seen in hyper-
glycemic islets would result in impaired insulin secretion and, in
turn, hyperglycemia, we used RNA interference (siRNA) to silence
the expression of 6 genes in INS-1 832/13 cells. We used RT-qPCR
Figure 3. Co-expression analysis of the 11 positively correlated genes against glucagon (GCG) expression in human pancreatic islets. R, correlation coefﬁcient; P, P-value.
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to demonstrate sufﬁcient knock-downefﬁciency that ranged from
50 to 85% (Fig. 5A). Silencing of PPP1R1A, FAM105A, PLCXD3 ENO2
andGNG5 signiﬁcantly reduced glucose-stimulated insulin secre-
tion after 1 h of incubation in 16.7 m glucose, whereas therewas
no effect of down-regulation of GLRA1 on insulin secretion
(Fig. 5B–F).
Association between SNPs in the selected genes and risk
of T2D in the DIAGRAM+ database
We also analyzed whether SNPs within a region spanning ±50 kb
up- and down-stream of the six selected genes were associated
with T2D in the DIAGRAM+ database. This analysis included
193 SNPs in or around the GLR1A gene, 94 SNPs in PPP1R1A, 114
SNPs in FAM105A, 304 SNPs in PLCXD3, 139 in GNG5 and 28 in
ENO2. While none of them as expected would pass the threshold
for genome-wide signiﬁcance, we cannot from the data exclude
that any SNP in these genes could be pathogenically involved
in T2D (Table 2).
SNP effect on gene expression (eQTLs)
Wealso analyzedwhether SNPs inﬂuenced gene expression in cis
(within 250 kb of the SNP). For analysis purposes, we identiﬁed a
single best ‘sentinel’ SNP for each gene, deﬁned as the SNP with
the lowest P-value per eQTL gene. Applying these criteria
and thresholds, we identiﬁed four cis-eQTLs in four genes. The
strongest eQTLs were seen for rs35039612 (ENO2), rs1512906
(PPP1R1A), rs2347598 (GLRA1) and rs26173 (FAM105A) (Fig. 6).
Discussion
In this study, we applied a novel approach to uncover potential
candidate genes that contribute to the pathophysiology of T2D.
Thematerial used included a large number of islets from cadaver
donors, in which DNA and RNA proﬁles could be related to glu-
cose-stimulated insulin secretion as well as HbA1c levels. We
ﬁrst tried to identify a gene pattern associated with low HbA1c
and normal or high insulin secretion (n = 518). To verify the link
between insulin secretion and HbA1c, we disrupted the expres-
sion of some of the genes showing this pattern. Secondly, we as-
sumed that genes associated with high HbA1c and low insulin
secretion could contribute to disease susceptibility (n = 128).
However, the latter scenario could also be secondary to elevated
HbA1c with the so-called glucotoxicity [for review, see Weir and
Bonner-Weir (23)]. To explore this possibility, we also exposed
human islets to short-term high glucose to identify genes
whose expressionwould change. These gene lists should provide
a resource for further studies (see gene description in the Supple-
mentary Material for the top correlated genes). We could only
select a small number of genes for follow-up studies (siRNA)
and focused on genes with little prior information on their poten-
tial involvement in the regulationof insulin secretion. These genes
are primarily expressed in β-cells and, therefore, the siRNA experi-
ments were performed in a clonal rat insulinoma cell line.
ATP2A3, PTEN and SYT13 from the positively correlated genes
were excluded, as they have previously been implicated in insulin
secretion and islet function. ATP2A3 plays a vital role in the se-
questration of cytosolic Ca2+ into the endoplasmic reticulum
(24). Several reportshave shown that loss ofATP2A3ordown-regu-
lation of gene expression in β-cellswas associatedwith diabetes in
db/db mice (19), Goto-Kakizaki Wistar (GK) rats (18) and humans
(17). SYT13 is amemberof the synaptotagmin family and involved
in β-cell exocytosis (25). Recently, we showed that siRNA silencing
of SYT13 expression reduced glucose-stimulated insulin secretion
in INS-1 cells, which suggests that SYT13 contributes to impaired
insulin secretion (22). PTEN is a phosphoinositide phosphatase
Figure 4. Effect of glucose exposure on gene expression. Human pancreatic islets (n = 51) treated with low (5.5 m) and high (18.9 m) glucose concentration for 24 h.
Analysis of differential expression by RNA-seq showed a similar down-regulation of ENO2 (P = 0.002) and GLRA1 (P = 0.02) as seen during chronic hyperglycemia. In
contrast, the expression of GNG5 (P = 0.0001) and PPP1R1A (P = 0.0002) was up-regulated by short-term elevated glucose. Glucose exposure had no effect on the
expression of FAM105A (P = 0.9) and PLCXD3 (P = 0.4).
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that regulates the PI3K/Akt signaling pathway (20). It was identi-
ﬁed as a negative regulator of insulin signaling with a major role
in regulating glucose metabolism via the Akt/PKB signaling path-
way (21). Additionally, one report has identiﬁed threemutations in
the PTEN gene in T2D patients, suggesting that the PTEN gene is
associated with insulin resistance and T2D (26).
PPP1R1Awas correlated positively with insulin secretion and
negatively with HbA1c. The gene has lower expression in diabetic
islets compared with non-diabetic islets (Fig. 2) but was up-
regulated by short-term exposure to high glucose (Fig. 4), suggest-
ing that the decreased expression in hyperglycemic islets hardly
is a consequence of hyperglycemia. RNA sequencing has also
veriﬁed higher expression in β-cells than that in α-cells or exo-
crine cells (16). Knock-down of PPP1R1A resulted in markedly re-
duced insulin secretion, suggesting that a high expression could
enhance insulinmetabolism–secretion coupling (Fig. 5). PPP1R1A
was previously found as a novel β cell marker with high-molar
protein abundance and β cell-restricted expression in human
pancreas (27). Moreover, using mass spectrometry of sorter-
puriﬁed β-cells, PPP1R1A was suggested as a biomarker for
acute β-cell destruction (28). PPP1R1A belongs to a family of 200
proteins (encoding inhibitor-1 proteins) that bind to and target
the isoforms of protein phosphatase 1 (PP-1) to their substrates
in the cell [for review, see Gregorio et al. (29)]. PPP1R1A is itself
regulated by protein phosphorylation. Another I-1, R6 (encoded
by PPP1R3D) regulates AMP kinase and its knock-down in MIN6
cells attenuated glucose-stimulated insulin secretion by impair-
ing dephosphorylation/inactivation of AMP kinase (30). In con-
trast, blockade of PP-1 acutely by the nonselective inhibitors
okadaic acid or Cal A decreased glucose-induced insulin secre-
tion of pancreatic β-cells owing to inhibition of Ca2+ inﬂux and
impaired regulation of vesicular fusion of secretory vesicles
(31,32). It remains to be demonstrated how long-term alteration
of PP-1 activity inﬂuences these mechanisms in the β-cell.
ENO2 was down-regulated in hyperglycemic islets and also by
exposure to high glucose in vitro (Figs. 2 and 4). Disruption of ENO2
resulted in impaired insulin secretion, suggesting that appropriate
expression of ENO2 is required for normal islet function (Fig. 4).
ENO2 functions as a neuron-speciﬁc enolase (NSE) in neurons,
glia and also neuro-endocrine cells (33,34). NSE is a phosphopyru-
vatehydratase,which is a keyenzyme in the conversionof glucose
to pyruvate. As glucose enters the cell, it has to be converted to
pyruvate for the formation of ATP in the mitochondria to initiate
depolarizationof the cell by closure of ATP-dependentK+-channels
and subsequently increased Ca2+ inﬂux by voltage-gated Ca2+-
channels (35). This strongly suggests that NSE could regulate
glycolysis within the β-cell and insulin secretion. Hence, it is con-
ceivable to hypothesize that decreased expression of ENO2 in pan-
creatic β-cells may contribute to increased susceptibility to T2D by
limiting pyruvate generation, leading to inadequate production of
ATP, causing impairedCa2+ inﬂuxandattenuated insulin secretion.
Further studies are required to elucidate the potential role of ENO2
in β-cell failure and the pathogenesis of hyperglycemia.
FAM105A correlated positively with insulin secretion and
negatively with HbA1c. The gene was down-regulated in hyper-
glycemic islets, but acute increase in glucose concentration
had no inﬂuence on its expression (Figs. 2 and 4). However,
Figure 5. Glucose-stimulated insulin secretion in transfected clonal β-cells.
(A) Knock-down efﬁciency of siRNA of PPP1R1A, ENO2, FAM105A, PLCXD3,
GNG5 and GLRA1 in INS-1 cells. (B) siRNA experiments for the above-listed
genes show insulin secretion in response to 2.8 m and 16.7 m glucose 72 h
after transfection as measured during 1 h of static incubation. Secretion was
expressed as fold increase (insulin secreted at 16.7 m/insulin secreted at
2.8 m glucose) and normalized for protein content (ng/mg/h). Data are shown
from three experiments. Bars represent mean ± SD. *<0.05, **<0.01.
Table 2. Association between SNPs in the six selected genes and T2D in the DIAGRAM+ database
Gene SNP Chromosome Position Risk allele P-value P-Genome-wide signiﬁcance
GLRA1 rs170020 5 151 324 751 A 1.10E − 03 2.60E – 04
PPP1R1A rs1153146 12 53 317 187 C 3.00E − 02 5.40E− 04
FAM105A rs153822 5 14 680 833 G 1.50E − 02 4.40E− 04
PLCXD3 rs17263168 5 41 320 500 C 3.20E − 03 1.60E− 04
ENO2 rs7955412 12 6 868 632 C 7.10E − 01 3.60E− 04
GNG5 rs6677436 1 84 687 888 T 5.30E − 01 1.80E− 03
SNPs within a region spanning ±50 kb up- and down-stream of the six selected genes were analyzed for association with T2D in the DIAGRAM+ database.
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knock-down of FAM105A resulted in a clear decrease in insulin
secretion suggesting that it could play a pathogenic role in dia-
betes (Fig. 5). FAM105A has previously been ascribed a role in
Amenorrhea (www.genecards.org). A paralog of this gene is
FAM105B, which is required for angiogenesis, craniofacial and
neuronal development by regulating the canonicalWnt signaling
(genecards.org). The cellular mechanisms how FAM105A inﬂu-
ences insulin secretion remain to be clariﬁed.
PLCXD3 correlated positively with insulin secretion and in-
versely with HbA1c and its disruption reduced insulin secretion
(Fig. 5). PLCDX3was down-regulated in islets fromhyperglycemic
donors, but short-term exposure to high glucose did not inﬂu-
ence its expression (Fig. 4).
PLCXDs are a subtype of the phosphatidylinositol-speciﬁc
phospholipase C (PLCs) protein family. PLCs are receptor-regulated
phosphodiesterases that regulate hormones, growth factors and
neurotransmitters by generating the calcium-mobilizing mes-
senger inositol-1,4,5-trisphosphate (IP3) and the membrane-
bound protein kinase C activator diacylglycerol (DAG) (36–39).
Several lines of evidence suggest that PLC plays an important
role in the regulation of insulin secretion in the pancreatic
β cells. In addition to receptor activation, the inﬂux of calcium
has been shown to activate PLC, resulting in exocytosis (40,41).
Such positive feedback is important in the regulation of insulin
secretion by neurotransmitters (42). Thus, the failure of PLC acti-
vation resulted in impairment of insulin secretion (43–45).
GLRA1 is an ion channel that binds glycine to increase chlor-
ide conductance. The genewas on top of the list showing positive
correlation with insulin and negative with HbA1c. The gene is
also down-regulated in hyperglycemic islets and in response to
high glucose exposure (Figs. 2 and 4). However, siRNA of the
GLRA1 gene did not inﬂuence insulin secretion (Fig. 4). In support
of this, a recent report by Li et al. showed that glycine does not
stimulate insulin secretion in human islets but rather increases
glucagon release instead (46). Additionally, GLRA1 showed a posi-
tive correlation with glucagon (GCG) expression in human islets
(Fig. 2). Glycine has been suggested as a biomarker for future
T2D risk, perhaps participating in the hyperglucagonemia of
the disease (47,48).
Somewhat surprisingly, the expression of the positively corre-
lated genes (associatedwith lowHbA1candhigh insulin secretion)
showed a very consistent positive correlation with the glucagon
gene, whereas the opposite was seen for the negatively correlated
genes. The positive correlation between proglucagon mRNA and
low HbA1c (Fig. 3) could point to a protective effect of the incretin
hormoneGLP-1, which potentiates insulin secretion, protects beta
cells from apoptosis and increases cell-to-cell coupling in human
islets (49). It has been demonstrated that 20% of human islet alpha
cells contain and release GLP-1 in response to stimulatory glucose
concentrations (50). GLP-1 production in the islet is rendered pos-
sible as this subpopulation, in contrast to the bulk of alpha cells,
expresses the prohormone convertase PC1/3, necessary for the
processing of the proglucagon peptide to GLP-1. In addition, islet
GLP-1 production is increased by exercise, an effect that appears
to be mediated by IL-6. Moreover, glucagon itself has been shown
to participate in GSIS in human islets, and alpha–beta cell contacts
improve insulin secretion caused by glucose (51–53). Future work
should focus on the further elucidation of the role of intra-islet
GLP-1 in the maintenance of beta cell function.
In contrast,GNG5expressioncorrelatednegativelywith insulin
secretion and positively with HbA1c, and its expression was up-
regulated in diabetic islets (Fig. 2). This could potentially represent
a homeostatic adaptation to the hyperglycemic milieu, as knock-
down of GNG5 in INS-1 cells resulted in decreased insulin secre-
tion (Fig. 5). This is also supported by the ﬁnding of up-regulation
of GNG5 in response to high glucose exposure (Fig. 4). GNG5
encodes an isoform of the Gγ subunit, which together with a Gβ
subunit forms a Gβγ dimer, and couples signals from G protein-
coupled receptors to activate adenylyl cyclases or potassium
channels (54–56). In β-cells, heterotrimeric G proteins are involved
in several regulatory pathways inﬂuencing glucose-stimulated in-
sulin secretion, such as through mediation of adrenergic inhib-
ition and effects on insulin granule exocytosis. Which speciﬁc
role GNG5wouldplay in β-cells isnot known (57,58), but disruption
Figure 6. cis-eQTL effects on four of the selected genes. SNP genotyped in human islets were analyzed for inﬂuence on gene expression (eQTL) in cis (within 250 kb of the
SNP) using array expression data. The strongest eQTLs were seen for rs35039612 (ENO2), rs1512906 (PPP1R1A), rs2347598 (GLRA1) and rs26173 (FAM105A).
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of GNG5 caused embryonic lethality inmice linked to reduction of
cardiac precursor cell numbers (59).
In conclusion, we introduced a novel approach to discover
new candidate genes involved in the pathogenesis of T2D. Five
genes PPP1R1A, FAM105A, PLCXD3, ENO2 and GNG5 were identi-
ﬁed and experimentally validated as potential players in the
pathogenesis of islet dysfunction in T2D. We also provide a list
of potential genes involved in protection from and susceptibility
to T2D based upon correlation between their expression in
human pancreatic islets and insulin secretion and glycemia
(HbA1c). This gene list should serve as a resource for future stud-
ies exploring their potential role in β-cell failure and the patho-
genesis of hyperglycemia and T2D.
Materials and Methods
Human pancreatic islets
Islets fromcadaverdonors (78 donors)were provided by theNordic
Islet Transplantation Program (www.nordicislets.org), Uppsala
University. All procedures were approved by the ethics commit-
tees at Lund University. Islets were obtained from 68 non-diabetic
donors (30 females, 37 males, age 59 ± 10, BMI 25.9 ± 3.5, HbA1c
5.5 ± 1.1 anddays of culture 3.5 ± 1.9) and10T2Ddonors (4 females,
6 males, age 60.7 ± 12, BMI 28.1 ± 4.5, HbA1c 7.1 ± 1.2 and days of
culture 2 ± 0.9). Purity of the islet preparations was assessed by di-
thizone staining amounted to 60.1 ± 20% in the T2D and 70 ± 17%
in the non-diabetic islets (P = 0.10). Insulin content was measured
as a surrogate marker for β-cell mass in pancreatic islets from
hyperglycemic (HbA1c > 6.0%) and normoglycemic (HbA1c < 6.0%)
donors, which revealed amodest and insigniﬁcant decrease in in-
sulin content in islets from hyperglycemic donors (4.8 ± 3.2 versus
5.6 ± 3.2 ng/ml in normoglycemic donors; P = 0.4). We also mea-
sured the contribution of exocrine and endocrine tissue as previ-
ously described (15). The estimated contribution of endocrine
tissue showed no difference between non-diabetic and T2D do-
nors (72 versus 68%, respectively, P = 0.29). RNA-seq showedhigher
insulin expression in non-diabetic donors [351 arbitrary unit (AU)]
compared with diabetic donors (255 AU; P < 0.05). The islets were
cultured in CMRL 1066 (ICN Biomedicals, Costa Mesa, CA, USA)
supplemented with 10 m/l HEPES, 2 m/l l-glutamine, 50 µg/ml
gentamicin, 0.25 µg/ml Fungizone (GIBCO, BRL, Gaithersburg,
MD, USA), 20 µg/ml ciproﬂoxacin (Bayer Healthcare, Leverkusen,
Germany) and 10 m/l nicotinamide at 37°C (5% CO2) prior to
RNA preparation.
Microarray gene expression in human pancreatic islets
RNAwas isolated with the AllPrep DNA/RNAMini Kit (Qiagen, Hil-
den, Germany). RNA quality and concentration were measured
using an Agilent 2100 bioanalyzer (Bio-Rad, Hercules, CA, USA)
andNanodropND-1000 equipment (NanoDrop Technologies,Wil-
mington, DE, USA). The microarrays (GeneChip® Human Gene 1.0
ST)were performedusing theAffymetrix standardprotocol aspre-
viously described (15). The array data were summarized and nor-
malized with Robust Multi-array Analysis method using the ligo
package from BioConductor. Also, batch correction was done
with COMBACT function from SVA package from Bioconductor.
All data are MIAME compliant, and the raw data have been depos-
ited in a MIAME database (GEO, accession number: GSE 50398 and
GSE 50397).
RNA sequencing
Human islets from 51 donors were divided in two pools of 3000 to
5000 islets and were then incubated in CMRL 1066 medium (ICN
Biomedicals) containing 5.5 m or 18.9 m glucose for 24 h. Fol-
lowing treatment, the total RNA including miRNAwas extracted
using miRNeasymini kit (Qiagen) and quality was assessed with
the 2200 Tapestation (Agilent Technologies). One microgram of
total RNA of sufﬁcient quality (RIN > 8) was used for sample prep-
aration for sequencingwith a TruSeq RNA sample preparation kit
(Illumina). The size selection was done using Agencourt AMPure
XP beads (Beckman Coulter) aiming at a fragment size of ∼300 bp.
The resulting libraries were quality controlled on a 2200 Tapesta-
tion (Agilent Technologies) before combining six samples into 1
pool for sequencing on 1 lane on a Flow cell sequenced on a
HiSeq 2000 (Illumina). Illumina Casava v.1.8.2 software was
used for base calling. Paired-end 101-bp-length output reads
were aligned to the human reference genome (hg19) with STAR
(60), and the number of reads aligned to speciﬁc transcripts was
counted usingHTSeq (61) (SimonAnders, Paul Theodor Pyl,Wolf-
gang Huber). Raw data were normalized using trimmed mean of
M-values and transformed using voom (limma R-package) before
linear modeling. The data extracted is part of an unpublished
data set.
Genotyping
Genotyping was performed on the Illumina HumanOmniExpress
12v1 C chips, and genotype calling was done with the Illumina
Genome studio software. All the samples passed standard geno-
type QC (quality control) metrics: sample call rate >98%.
Glucose-stimulated insulin secretion
Islets were hand-picked under a stereomicroscope and pre-incu-
bated for 30 min at 37°C in Krebs Ringer bicarbonate (KRB) buffer
(pH 7.4) containing (in m) 120 NaCl, 25 NaHCo3, 4.7 KCl, 1.2
MgSO4, 2.5 CaCl2, 1.2 KH2PO, 10 HEPES supplemented with
0.1% bovine serum albumin, N-2 hydroxyethylpiperazine-N′-2-
ethanesulfonic acid (10 mmol/1) and 1 m glucose. Each incuba-
tion vial contained 12 islets in 1.0 ml KRB buffer solution andwas
treated with 95% O2–5% CO2 to obtain constant pH and oxygen-
ation. After pre-incubation, the buffer was changed to a KRB buf-
fer containing either 1 m (basal secretion) or 16.7 m glucose
(stimulated secretion). The islets were then incubated for 1 h at
37°C in a metabolic shaker (30 cycles per min). Immediately
after incubation, an aliquot of the mediumwas removed for ana-
lysis of insulin using a radioimmunoassay kit (Euro-Diagnostica,
Malmö, Sweden). Insulin content in homogenized human islets
was assessed by ELISA (Mercodia, Uppsala, Sweden), and values
were normalized to the total DNA in each sample as determined
by a ﬂuorometric assay (Quant-iT Picogreen, Invitrogen Molecu-
lar Probes, Stockholm, Sweden).
Culturing of INS-1 cell line
INS-1 832/13 is a clonal ß-cell line derived from INS-1 rat insulino-
ma cells containing the human pro-insulin gene (18,19). Cells
were cultured at 37°C in humid environment with 95% O2/5%
CO2 and split 1 : 4 by using 0.05% trypsin-EDTA (Invitrogen). We
used RPMI 1640 culture medium (Gibco) containing 11.1 m
D-glucose, 10% fetal bovine serum (Sigma), 5 ml penicillin/strep-
tomycin (1000 µ/10 mg/ml; Sigma), 5.6 ml Hepes (1, Sigma),
2 m -glutamine (200 m, Sigma), 1 m sodium pyruvate
(Sigma) and 50 µ ß-mercaptoethanol (14.3M, Sigma).
RNA interference and insulin secretion assay
Clonal INS-1 832/13 β-cells were cultured as previously described
(15,20) and transfected using a mixture of DharmaFECT® 1
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(Dharmacon; Lafayette, CO, USA) and the respective siRNAs. Dif-
ferent sets of siRNA sequences were purchased with siRNA iden-
tiﬁcation numbers ID: s130439 and 130437 (GLRA1), s133049 and
s133049 (PPP1R1A), s160229 and 160230 (FAM105A), s160317 and
s160319 (PLCXD3), s127701 and s127702 (ENO2), and s135096
and s135097 (GNG5) (Ambion). For control purposes, a previously
described control sequence Silencer® Negative Control #2 from
Ambion was employed. Cells were cultured in medium for 72 h
at 37°C in the presence of 40 n siRNA in 24-well cell culture mi-
croplates. After transfection, insulin secretion measurements
were performed. Conﬂuent plates containing transfected INS1–
832/13 cells were washed twice with 1 ml pre-warmed Secretion
Assay Buffer (SAB), pH 7.2 (114 mNaCl, 4.7 mKCl, 1.2 m KH2-
PO4, 1.16 m MgSO4, 20 m HEPES, 2.5 m CaCl2, 25.5 m
NaHCO3 and 0.2% bovine serum albumin) containing 2.8 m glu-
cose. The cells were then pre-incubated for 2 hours in new 2 ml
SAB with 2.8 m glucose. Subsequently, separate wells were in-
cubated for 1 h in 1 ml SAB containing either 2.8 m or 16.7 m
glucose. Secreted insulin was measured in the supernatant
using Coat-a-Count Insulin radioimmunoassay kit (Siemens),
and the values were normalized using total protein content indi-
vidually for each well.
Quantitative RT-qPCR
Total RNA from transfected INS-1 cells was performed 48 h post-
transfection using RNeasy Plus Mini Kit 50 (Qiagen). Assessment of
quality and quantity of extracted RNAwas performed using Nano-
Drop ND-1000 Spectrophotometer (Thermo Fisher Scientiﬁc, Inc.,
Waltham,MA, USA). Synthesis of cDNA fromextracted RNAwas per-
formed by using Fermentas RevertAid H Minus First Strand cDNA
Synthesis Kit (Thermo Fisher Scientiﬁc, Inc.). Knock-down efﬁciency
was assessed by RT-qPCR of the target genes as described earlier
using the following Taqman® gene expression assays (Life Technolo-
gies): GLRA1 (Rn00565582_m1), PPP1R1A (Rn00575374_m1), FAM105A
(Rn01524442_m1), PLCXD3 (Rn01762608_m1), ENO2 (Rn00595017_m1)
and GNG5 (Rn00821205_g1) in triplicate on 384-well plates. qPCR
was performed in ABI 7900 platform (Applied Biosystems, Foster
City, CA, USA). The rat HPRT1 (Rn01527840_m1) was used to
normalize gene expression by ΔΔCt method, where the ﬁnal
normalized quantity was expressed as 2(Ct target−Ct control).
cis-eQTL analysis
The cis-eQTL analysis of the genes GLRA1, PPP1R1A, PLCXD3,
FAM105A, ENO2 and GNG5 was performed on islets microarray
from 89 individuals. A linear model adjusting for age and sex as
implemented in the RMatrix eQTL package (21) was used to com-
pute associations between these gene expression levels and SNPs
within 250 kb up- or down-stream of each of these genes.
DIAGRAM database
DIAGRAM (DIAbetes Genetics Replication AndMeta-analysis) is a
meta-analysis of eight GWASs for T2D (WTCCC, DGI, FUSION, De-
code, DGDG, KORAgen, Rotterdam and EUROSPAN) comprising
8130 T2D cases and 38 987 controls of European descent. Details
of the samples and the GWAS platforms used in each scan have
been described elsewhere (8). Brieﬂy, analyses of ﬁxed-effects,
additive-model for 2 426 886 imputed and genotyped SNPs were
combined using the inverse-variance method. Imputation was
performed using IMPUTE (http://mathgen.stats.ox.ac.uk/impute/
impute.html/). The replication sample included in silico data
from independent three GWASs (ARIC, Nurses’ Health Study,
Framingham Heart Study: 2832 cases, 15 843 controls) and
de novo genotyping (31 580 cases and 44 082 controls) totaling
34 412 cases and 59 925 control subjects of European descent.
Statistical analysis
Differences in expression levels were analyzed by Student’s t-test
or nonparametric Mann–Whitney test (two tails). Expression cor-
relation with Glucagon (GCG) was analyzed by nonparametric
Spearman’s test. The Global correlation of gene expression with
HbA1c and insulin secretion was done using Spearman’s tests in
R. All Statistical tests were performed using the Statistical Pack-
age for the Social Sciences (SPSS) version 19.0 software (SPSS,
Chicago, IL, USA). P-values of <0.05were considered as signiﬁcant
for all tests.
Supplementary Material
Supplementary Material is available at HMG online.
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